Cargando…
Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?
Pulmonary arterial hypertension (PAH) is a rare disease that carries a poor prognosis. For 45 years, the definition of pulmonary hypertension (PH) has been a mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg, based on expert opinion. Recent data indicate that the mortality risk starts in the mPAP ra...
Autores principales: | Huston, Jessica H., Frantz, Robert P., Brittain, Evan L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469279/ https://www.ncbi.nlm.nih.gov/pubmed/30931829 http://dx.doi.org/10.1177/2045894019844994 |
Ejemplares similares
-
Are anticoagulants still indicated in pulmonary arterial hypertension?
por: Olschewski, Horst, et al.
Publicado: (2018) -
Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension
therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020) -
United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications
por: Elliott, C. Gregory, et al.
Publicado: (2019) -
The use of chromoendoscopy for surveillance of inflammatory bowel disease
por: Lichtenstein, Gary R., et al.
Publicado: (2018) -
Trade in wild animals: a disaster ignored
por: The Lancet Infectious Diseases
Publicado: (2003)